These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Identification and functional characterization of allosteric agonists for the G protein-coupled receptor FFA2. Lee T; Schwandner R; Swaminath G; Weiszmann J; Cardozo M; Greenberg J; Jaeckel P; Ge H; Wang Y; Jiao X; Liu J; Kayser F; Tian H; Li Y Mol Pharmacol; 2008 Dec; 74(6):1599-609. PubMed ID: 18818303 [TBL] [Abstract][Full Text] [Related]
4. Structure-Activity Relationship Explorations and Discovery of a Potent Antagonist for the Free Fatty Acid Receptor 2. Højgaard Hansen A; Christensen HB; Pandey SK; Sergeev E; Valentini A; Dunlop J; Dedeo D; Fratta S; Hudson BD; Milligan G; Ulven T; Rexen Ulven E ChemMedChem; 2021 Nov; 16(21):3326-3341. PubMed ID: 34288488 [TBL] [Abstract][Full Text] [Related]
5. Defining the molecular basis for the first potent and selective orthosteric agonists of the FFA2 free fatty acid receptor. Hudson BD; Due-Hansen ME; Christiansen E; Hansen AM; Mackenzie AE; Murdoch H; Pandey SK; Ward RJ; Marquez R; Tikhonova IG; Ulven T; Milligan G J Biol Chem; 2013 Jun; 288(24):17296-312. PubMed ID: 23589301 [TBL] [Abstract][Full Text] [Related]
6. N-Thiazolylamide-based free fatty-acid 2 receptor agonists: Discovery, lead optimization and demonstration of off-target effect in a diabetes model. Hoveyda HR; Fraser GL; Zoute L; Dutheuil G; Schils D; Brantis C; Lapin A; Parcq J; Guitard S; Lenoir F; Bousmaqui ME; Rorive S; Hospied S; Blanc S; Bernard J; Ooms F; McNelis JC; Olefsky JM Bioorg Med Chem; 2018 Oct; 26(18):5169-5180. PubMed ID: 30253886 [TBL] [Abstract][Full Text] [Related]
7. Selective orthosteric free fatty acid receptor 2 (FFA2) agonists: identification of the structural and chemical requirements for selective activation of FFA2 versus FFA3. Schmidt J; Smith NJ; Christiansen E; Tikhonova IG; Grundmann M; Hudson BD; Ward RJ; Drewke C; Milligan G; Kostenis E; Ulven T J Biol Chem; 2011 Mar; 286(12):10628-40. PubMed ID: 21220428 [TBL] [Abstract][Full Text] [Related]
8. The first synthetic agonists of FFA2: Discovery and SAR of phenylacetamides as allosteric modulators. Wang Y; Jiao X; Kayser F; Liu J; Wang Z; Wanska M; Greenberg J; Weiszmann J; Ge H; Tian H; Wong S; Schwandner R; Lee T; Li Y Bioorg Med Chem Lett; 2010 Jan; 20(2):493-8. PubMed ID: 20005104 [TBL] [Abstract][Full Text] [Related]
9. Agonism and allosterism: the pharmacology of the free fatty acid receptors FFA2 and FFA3. Milligan G; Stoddart LA; Smith NJ Br J Pharmacol; 2009 Sep; 158(1):146-53. PubMed ID: 19719777 [TBL] [Abstract][Full Text] [Related]
10. Mutational analysis of G-protein coupled receptor--FFA2. Swaminath G; Jaeckel P; Guo Q; Cardozo M; Weiszmann J; Lindberg R; Wang Y; Schwandner R; Li Y Biochem Biophys Res Commun; 2011 Feb; 405(1):122-7. PubMed ID: 21216233 [TBL] [Abstract][Full Text] [Related]
11. Synthesis, Activity, and Docking Study of Novel Phenylthiazole-Carboxamido Acid Derivatives as FFA2 Agonists. Ma L; Wang T; Shi M; Fu P; Pei H; Ye H Chem Biol Drug Des; 2016 Jul; 88(1):26-37. PubMed ID: 26808470 [TBL] [Abstract][Full Text] [Related]
12. Discovery and optimization of an azetidine chemical series as a free fatty acid receptor 2 (FFA2) antagonist: from hit to clinic. Pizzonero M; Dupont S; Babel M; Beaumont S; Bienvenu N; Blanqué R; Cherel L; Christophe T; Crescenzi B; De Lemos E; Delerive P; Deprez P; De Vos S; Djata F; Fletcher S; Kopiejewski S; L'Ebraly C; Lefrançois JM; Lavazais S; Manioc M; Nelles L; Oste L; Polancec D; Quénéhen V; Soulas F; Triballeau N; van der Aar EM; Vandeghinste N; Wakselman E; Brys R; Saniere L J Med Chem; 2014 Dec; 57(23):10044-57. PubMed ID: 25380412 [TBL] [Abstract][Full Text] [Related]
13. Non-equivalence of Key Positively Charged Residues of the Free Fatty Acid 2 Receptor in the Recognition and Function of Agonist Versus Antagonist Ligands. Sergeev E; Hansen AH; Pandey SK; MacKenzie AE; Hudson BD; Ulven T; Milligan G J Biol Chem; 2016 Jan; 291(1):303-17. PubMed ID: 26518871 [TBL] [Abstract][Full Text] [Related]
14. Conserved polar residues in transmembrane domains V, VI, and VII of free fatty acid receptor 2 and free fatty acid receptor 3 are required for the binding and function of short chain fatty acids. Stoddart LA; Smith NJ; Jenkins L; Brown AJ; Milligan G J Biol Chem; 2008 Nov; 283(47):32913-24. PubMed ID: 18801738 [TBL] [Abstract][Full Text] [Related]
15. Ligands at the Free Fatty Acid Receptors 2/3 (GPR43/GPR41). Milligan G; Bolognini D; Sergeev E Handb Exp Pharmacol; 2017; 236():17-32. PubMed ID: 27757758 [TBL] [Abstract][Full Text] [Related]
16. Selective FFA2 Agonism Appears to Act via Intestinal PYY to Reduce Transit and Food Intake but Does Not Improve Glucose Tolerance in Mouse Models. Forbes S; Stafford S; Coope G; Heffron H; Real K; Newman R; Davenport R; Barnes M; Grosse J; Cox H Diabetes; 2015 Nov; 64(11):3763-71. PubMed ID: 26239054 [TBL] [Abstract][Full Text] [Related]
17. A Novel Allosteric Activator of Free Fatty Acid 2 Receptor Displays Unique Gi-functional Bias. Bolognini D; Moss CE; Nilsson K; Petersson AU; Donnelly I; Sergeev E; König GM; Kostenis E; Kurowska-Stolarska M; Miller A; Dekker N; Tobin AB; Milligan G J Biol Chem; 2016 Sep; 291(36):18915-31. PubMed ID: 27385588 [TBL] [Abstract][Full Text] [Related]
18. In silico modelling and molecular dynamics simulation studies of thiazolidine based PTP1B inhibitors. Mahapatra MK; Bera K; Singh DV; Kumar R; Kumar M J Biomol Struct Dyn; 2018 Apr; 36(5):1195-1211. PubMed ID: 28393626 [TBL] [Abstract][Full Text] [Related]